RxDoctor Payments Data

Kerrilynn Hennessey, MD

Cardiovascular Disease · Lebanon, NHNPI 1952747446

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $965 of the $1,235 with a category attached, or 78.2%. Abbott accounts for 85.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $1,087 and has fallen 92.3% since, to $84 in 2025.

$1,235in general payments, 2019–2025

Across 14 payments — averaging $88.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$99
  • Johnson & Johnson$35
  • E.r. Squibb & Sons, L.L.C.$23
  • AstraZeneca$18
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7

What the payments were for

  • Travel & lodging$96578%
  • Food & beverage$27022%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,235 in reported general payments places this provider in the 55th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$160,574
Medicare patients
2,314
Services billed
3,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$235,796
JardianceEmpagliflozin114$133,692
Repatha SureclickEvolocumab99$120,249
EntrestoSacubitril/Valsartan64$63,288
XareltoRivaroxaban56$50,960
Praluent PenAlirocumab50$41,441
FarxigaDapagliflozin Propanediol22$24,819
Ezetimibe136$5,489
Metoprolol Succinate310$5,115
NexletolBempedoic Acid11$4,407
Atorvastatin Calcium271$3,869
Rosuvastatin Calcium187$3,140
Spironolactone135$1,328
Amiodarone Hcl68$1,301
Torsemide39$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$35$50,96056 claims
AstraZenecaFarxiga$18$24,81922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Lebanon

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →